Sumi Agro Europe Limited v. Syngenta Limited

UPC-000890

This appeal concerned provisional measures in a patent infringement dispute over European Patent EP 2 152 073 relating to herbicidal compositions. The Court of Appeal of the Unified Patent Court largely upheld the Munich Local Division's order finding that Sumi Agro's 'Kagura' herbicide more likely than not infringed the patent, while adding Romania to the territorial scope and reversing the cost decision to order Sumi Agro to bear Syngenta's costs.

Jurisdiction
European UPC
Court
Luxembourg (LU)
Case Number
UPC-000890
Judge(s)
and legally qualified judge Ingeborg Simonsson; and judge; Arwed Burrichter; Anna Hedberg; IMPUGNED ORDER OF THE COURT OF FIRST INSTANCE Munich Local Division

Detailed Summary

Syngenta Limited, the registered proprietor of European Patent EP 2 152 073 ('Herbicide Compositions'), applied for provisional measures against Sumi Agro Limited and Sumi Agro Europe Limited before the Munich Local Division. The patent, filed on 19 May 2008 with priority from GB 0709710 (21 May 2007), was granted on 15 April 2015. Claim 1 of the patent covers an herbicidal composition comprising at least one sulfonylurea herbicide, at least one HPPD-inhibiting herbicide, and at least one saturated or unsaturated fatty acid from 1% to 95% by weight.

The contested embodiment was a herbicide marketed by Sumi Agro under the trade names 'Kagura' or 'Genki', containing mesotrione and nicosulfuron as active ingredients, sold as an oil dispersion for weed control in maize. Syngenta obtained samples of Kagura in the Czech Republic in June 2023 and in Bulgaria on 4 July 2024, and alleged that the product contained fatty acids (palmitic acid, stearic acid, oleic acid, and linoleic acid) in excess of 1% by weight. Sumi Agro refuted this, arguing that the rapeseed oil used as diluent in its UPC-territory product contained only 0.0% to 0.5% free fatty acids and that no additional fatty acid ingredient was included.

Sumi Agro also challenged the validity of the patent based on EP 0 915 652 B1 (EP 652), arguing lack of novelty and inventive step, which Syngenta refuted.

On 27 August 2024, the Munich Local Division ordered provisional measures against Sumi Agro, finding it more likely than not that the 2023 version of Kagura literally infringed claim 1. The Local Division reasoned that as claim 1 is a product claim, it was sufficient for Syngenta to show that fatty acids were present in the required concentration, even if the percentage increased over time due to hydrolysis during the product's 2-year shelf life. The injunction covered multiple UPC Contracting Member States.

Sumi Agro appealed, raising issues including infringement, validity, necessity, urgency, weighing of interests, territorial scope, and security. On infringement, the Court of Appeal found that the contested embodiment more likely than not made literal use of the technical teaching of claim 1, noting that the skilled person would understand that fatty acids in the composition could originate from the oil component. On validity, the Court found that Sumi Agro had not convincingly demonstrated that the patent was more likely invalid than not, particularly regarding the technical effect and the skilled person's assessment of the prior art.

Regarding territorial scope, the Court of Appeal held that there are no transitional rules connected to Art. 34 UPCA, and when a UPC Signatory State ratifies and accedes, the application of Art. 34 UPCA should be automatic from the day of accession. Accordingly, Romania was added to the territorial scope of the injunction.

On necessity, the Court found that a move from a market situation with only one product to one with two competing products could be expected to lead to permanent price erosion, making the provisional injunction necessary. The requirements of urgency and weighing of interests were also met.

Regarding security for enforcement, the Court of Appeal found that Sumi Agro had not substantiated any undue burden in enforcing a UPC compensation order in the UK, noting that both parties are UK registered companies, and that any enforcement would be between UK companies in the UK.

On costs, the Court of Appeal reversed the Local Division's decision, holding that a cost decision should be issued in inter partes proceedings for provisional measures since it concludes the action, and ordered Sumi Agro to bear the reasonable and proportionate legal costs and other expenses incurred by Syngenta both at first instance and on appeal.

The final order: (1) The appeal was rejected except for the cost decision, with Romania added to the territorial scope; (2) The cost decision was reversed, with Sumi Agro ordered to bear Syngenta's costs; (3) All other requests were dismissed.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Luxembourg (LU). Understanding the court's reasoning in Sumi Agro Europe Limited vs Syngenta Limited is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentUPC-000902

GISELA MAYER GmbHvsRespondent

1 Division Locale de Paris UPC_CFI_363/2024 Ordonnance de procédure du Tribunal de première instance de la Juridiction unifiée du brevet, rendue le 26/02/2025 Concernant une demande en garantie des frais (Règle 158 Rdp) REQUÉRANT - DEFENDEUR GISELA MAYER GmbH Litzelsdorfer Straße 3 87700 - Memmingen

patentUPC_F878C85C67

Maxell, Ltd.vsSamsung Electronics Co., Ltd. et al.

Maxell, Ltd., proprietor of European patent EP 2 061 230 relating to a portable terminal, information processing apparatus and content display system, sued Samsung Electronics entities for infringement of device claims 1, 2, 5 and 6 with Galaxy smartphones and tablets. Samsung counterclaimed for full revocation, alleging lack of novelty, lack of inventive step, and added matter. The Court of First Instance of the Unified Patent Court (The Hague Local Division) found the patent invalid for lacking an inventive step and revoked it in its entirety, dismissing Maxell's infringement action and ordering Maxell to pay Samsung's costs.

patentUPC-000435

ASUS Computer GmbH, ASUSTeK Italy S.r.l., ASUS France S.a.r.l., ASUS Europe B.V., Ninepoint GmbHvsRespondent

This procedural order concerned a request by Defendants 2 to 6 (ASUS-related entities and Ninepoint GmbH) to extend the time period for submitting their statement of defence and any counterclaim for revocation in a patent infringement action concerning European patent EP 3 849 157. The defendants argued that the time period should run from when they obtained access to the unredacted version of exhibit BB1, which contained an agreement between the Claimant and the patent's co-owner. The court granted a one-week extension, extending the deadline to 30 September 2025, finding that the extension was sufficient to compensate for the delayed access to evidence.

patentUPC_C0C65FC322

GlaxoSmithKline Biologicals SAvsModerna Netherlands B.V., Moderna Biotech Distributor UK Ltd

This order concerns proceedings involving two divisional European patents (EP4066856 and EP4226941) owned by GlaxoSmithKline Biologicals SA (GSK) against multiple Moderna entities. Both patents were revoked at the European Patent Office: EP941 by the Opposition Division on June 24, 2026, and EP856 by the Technical Board of Appeal on July 20, 2026, both for lack of novelty. The Court disposed of the counterclaim action regarding EP856 as devoid of purpose, ordered GSK to bear Moderna's costs, and postponed its decision on whether to stay the remaining proceedings pending the written grounds of the TBA decision.

patentUPC_B850B9DE31

Qualcomm Incorporated, San Diego, United States, Qualcomm Technologies, Inc., San Diego, United StatesvsNetwork System Technologies LLC, Portland, United States

In this legal proceeding before Court of Appeal (decision issued on 2026-07-15) under reference UPC_B850B9DE31, Qualcomm Incorporated, San Diego, United States, Qualcomm Technologies, Inc., San Diego, United States appeared in dispute with Network System Technologies LLC, Portland, United States concerning patent rights and legal remedies.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call